Drug intervention

DRUG3 trials

Sponsors

University Hospital, Angers, Shanghai Junshi Bioscience Co., Ltd., Centre Hospitalier Regional de Huy

Conditions

Alzheimer's DiseaseGait ApraxiaImpaired CognitionNSCLCOncology

Phase 2

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

CompletedNCT03513666

Shanghai Junshi Bioscience Co., Ltd.NSCLC

Start: 2018-04-09End: 2022-08-12Updated: 2023-08-23

Unknown Phase

Alzheimer's Disease and Related Disorders

University Hospital, AngersAlzheimer's Disease, Gait Apraxia, Impaired Cognition

Start: 2009-11-30End: 2017-11-30Target: 700Updated: 2011-03-15

Comparaison Between Digital and Drug Induced Sedation in Veinous Access Device Implantation

CompletedNCT05815056

Centre Hospitalier Regional de HuyOncology

Start: 2022-03-01End: 2022-08-25Updated: 2023-04-18

Related Papers

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

Canadian Respiratory Journal2023-06-214 citations

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.

2021-10-1578 citations

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

Journal of Clinical Oncology2020-05-2014 citations

Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.

2016-09-014 citations

Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.

2013-11-2118 citations